Home  »  Finance   »  Are we looking at the next big move in Nektar Ther...

Are we looking at the next big move in Nektar Therapeutics (NKTR)?

Nektar Therapeutics (NASDAQ: NKTR) is 18.18% higher on its value in year-to-date trading and has touched a low of $15.40 and a high of $26.75 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NKTR stock was last observed hovering at around $20.25 in the last trading session, with the day’s loss setting it -0.16% off its average median price target of $25.00 for the next 12 months. It is also 42.6% off the consensus price target high of $35.00 offered by 13 analysts, but current levels are -0.45% lower than the price target low of $20.00 for the same period.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently trading at $20.09, the stock is 2.78% and -5.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.72 million and changing -0.79% at the moment leaves the stock 3.30% off its SMA200. NKTR registered 2.08% gain for a year compared to 6-month gain of 21.91%. The firm has a 50-day simple moving average (SMA 50) of $20.29 and a 200-day simple moving average (SMA200) of $19.11.

The stock witnessed a 2.97% loss in the last 1 month and extending the period to 3 months gives it a 8.95%, and is -0.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.57% over the week and 4.20% over the month.

Nektar Therapeutics (NKTR) has around 718 employees, a market worth around $3.74B and $152.90M in sales. Distance from 52-week low is 30.50% and -24.90% from its 52-week high. The company has generated returns on investments over the last 12 months (-39.50%).

Nektar Therapeutics (NKTR) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Nektar Therapeutics (NKTR) is a “Overweight”. 13 analysts offering their recommendations for the stock have an average rating of 2.50, where 8 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Nektar Therapeutics is expected to release its quarterly report on 08/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.72 with sales reaching $26.9M over the same period.The EPS is expected to grow by 1.20% this year, but quarterly earnings will post -27.50% year-over-year. Quarterly sales are estimated to shrink -46.80% in year-over-year returns.

Nektar Therapeutics (NKTR) Top Institutional Holders

356 institutions hold shares in Nektar Therapeutics (NKTR), with 1.47M shares held by insiders accounting for 0.81% while institutional investors hold 96.39% of the company’s shares. The shares outstanding are 179.72M, and float is at 177.86M with Short Float at 11.07%. Institutions hold 95.62% of the Float.

The top institutional shareholder in the company is Invesco Ltd. with over 35.46 million shares valued at $602.77 million. The investor’s holdings represent 19.45% of the NKTR Shares outstanding. As of Dec 30, 2020, the second largest holder is FMR, LLC with 18.95 million shares valued at $322.14 million to account for 10.40% of the shares outstanding. The other top investors are Primecap Management Company which holds 18.44 million shares representing 10.12% and valued at over $313.49 million, while Blackrock Inc. holds 10.08% of the shares totaling 18.38 million with a market value of $312.43 million.

Nektar Therapeutics (NKTR) Insider Activity

A total of 48 insider transactions have happened at Nektar Therapeutics (NKTR) in the last six months, with sales accounting for 29 and purchases happening 19 times. The most recent transaction is an insider sale by CHESS ROBERT, the company’s Director. SEC filings show that CHESS ROBERT sold 8,000 shares of the company’s common stock on Apr 14 at a price of $18.98 per share for a total of $0.15 million. Following the sale, the insider now owns 0.28 million shares.

Nektar Therapeutics disclosed in a document filed with the SEC on Feb 16 that Zalevsky Jonathan (Chief R&D Officer) sold a total of 24,141 shares of the company’s common stock. The trade occurred on Feb 16 and was made at $22.37 per share for $0.54 million. Following the transaction, the insider now directly holds 0.27 million shares of the NKTR stock.

Still, SEC filings show that on Feb 16, Wilson Mark Andrew (SVP & General Counsel) disposed off 2,173 shares at an average price of $22.37 for $48610.0. The insider now directly holds 76,727 shares of Nektar Therapeutics (NKTR).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Nektar Therapeutics (NKTR): Who are the competitors?

The company’s main competitors (and peers) include AstraZeneca PLC (AZN) that is trading 1.28% up over the past 12 months. Pfizer Inc. (PFE) is 6.85% up on the 1-year trading charts. Short interest in the company’s stock has risen 1.3% from the last report on Apr 14, 2021 to stand at a total of 19.68 million short shares sold with a short interest ratio of 23.76.

Related Posts

110500

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam